Zydus Lifesciences shares in focus after USFDA approval for Dasatinib tablets.

Zydus Lifesciences has secured 415 regulatory approvals and filed 483 Abbreviated New Drug Applications (ANDAs) as of December 31, 2024, since FY 2003-04.